Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Autolus Therapeutics PLC
AUTL
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.66
0.07
4.4%
Dern. MÀJ: Oct 20, 7:53 PM
$1.67
0.08
5.03%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Autolus Therapeutics Financials
Autolus Therapeutics (AUTL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est
Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.
Benzinga Newsdesk
PRO
Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 16.67 percent increase over losses of $(0.18) per share
Benzinga Newsdesk
PRO
Autolus Therapeutics Sees FY2026 Sales $120.000M-$135.000M vs $130.062M Est
Autolus Therapeutics (NASDAQ:AUTL) sees FY2026 sales of $120.000 million-$135.000 million vs $130.062 million analyst estimate.
Benzinga Newsdesk
PRO
Autolus Therapeutics Q1 EPS $(0.27), Inline, Sales $26.218M Beat $26.160M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 3.85 percent decrease over losses of $(0.26) per share from the same period last year.
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
Earnings Scheduled For March 27, 2026
Benzinga Insights
